(GLOBE NEWSWIRE) – ThromboGenics NV, an integrated biopharmaceutical company focused on developing and commercializing innovative ophthalmic medicines, is pleased to announce the appointment of Dominique Vanfleteren as its new Chief Financial Officer (CFO) with immediate effect.
Dominique Vanfleteren has over 25 years of experience in senior finance, operational, control and reporting roles within quoted international biopharmaceutical companies.
Before joining ThromboGenics, Dominique spent 12 years at UCB, a global biopharmaceutical company, where he held a number of international managerial finance positions, the latest being the CFO of UCB’s Asia Pacific Operations, operating from Brussels and Shanghai.
Prior to joining UCB, Dominique worked for GSK during 16 years. He held a number of senior finance positions in Brussels and London, his latest being Finance Director of GSK’s Diversified Healthcare Services Europe.
Dr Patrik De Haes, Chief Executive Officer of Thrombogenics, said: “I am delighted to welcome Dominique Vanfleteren to Thrombogenics as our new CFO. Dominique is bringing significant financial experience from within the biopharmaceutical industry and I am confident that he will prove a great addition to our senior management team as we look to execute our strategy as announced in mid-2014.”
Commenting on his appointment, Dominique Vanfleteren said: “I am very pleased to be joining ThromboGenics and excited to be able to contribute to the Company’s future success based on the further development of JETREA®, as well as on its broader strategy of developing innovative medicines for the treatment of ophthalmic diseases focused on diabetic retinopathy.”
Source:ThromboGenics NV
In 2017, Sanofi partnered with the Lebanon, New Hampshire-based ImmuNext to develop an antibody for autoimmune diseases like lupus and multiple sclerosis, which included giving Sanofi a worldwide license to develop frexalimab. The agreement involved milestone payments upto $500 million.
Global manufacturer for the pharmaceutical, biotech and nutraceutical markets, Lonza has announced that it has acquired Synaffix, a biotech company focused on the commercialisation of its clinical stage technology platform for the development of antibody-drug conjugates (ADCs).
In its hunt for the new head of its pharmaceutical systems business—which makes syringes, self-injection systems and other drug delivery devices for 70% of the top 100 drugmakers in the world, according to the company—BD landed on a candidate with plenty of experience among that customer group.
